FBIO FORTRESS BIOTECH INC.

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference

MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the following sessions at the H.C. Wainwright 1st Annual Royalty Company Virtual Conference, taking place on Tuesday, May 13, 2025:

  • 2:00 p.m. – 2:30 p.m. ET: Fireside Chat
  • 5:00 p.m. – 6:00 p.m. ET: Panel Presentation: Development Stage Companies – Where Do Royalty and Tech Platform Plays Fit?

To register for the conference, visit .

About Fortress Biotech

Fortress Biotech, Inc. (“Fortress”) is an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue. The company has eight marketed prescription pharmaceutical products and over 20 programs in development at Fortress, at its majority-owned and majority-controlled partners and subsidiaries and at partners and subsidiaries it founded and in which it holds significant minority ownership positions. Fortress’ portfolio is being commercialized and developed for various therapeutic areas including oncology, dermatology, and rare diseases. Fortress’ model is focused on leveraging its significant biopharmaceutical industry expertise and network to further expand and advance the company’s portfolio of product opportunities. Fortress has established partnerships with some of the world’s leading academic research institutions and biopharmaceutical companies to maximize each opportunity to its full potential, including AstraZeneca, City of Hope, Fred Hutchinson Cancer Center, Nationwide Children’s Hospital and Sentynl. For more information, visit .

Company Contact:

Jaclyn Jaffe

Fortress Biotech, Inc.

(781) 652-4500

Media Relations Contact:

Tony Plohoros

6 Degrees

(908) 591-2839

  



EN
07/05/2025

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on FORTRESS BIOTECH INC.

 PRESS RELEASE

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Roya...

Fortress Biotech to Participate in the H.C. Wainwright 1st Annual Royalty Company Virtual Conference MIAMI, May 07, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty revenue, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in the following sessions at the H.C. Wainwright 1st Annual Royalty Company Virtual Co...

 PRESS RELEASE

Fortress Biotech Reports 2024 Financial Results and Recent Corporate H...

Fortress Biotech Reports 2024 Financial Results and Recent Corporate Highlights Emrosi™ approved by FDA for the treatment of inflammatory lesions of rosacea in adults, with commercial launch underway; initial distribution ongoing and first prescriptions filled Fortress subsidiary Checkpoint Therapeutics to be acquired by Sun Pharma; Checkpoint’s lead product, UNLOXCYT™, approved by FDA for the treatment of metastatic or locally advanced cutaneous squamous cell carcinoma FDA accepted New Drug Application filing for priority review for CUTX-101 to treat Menkes disease; PDUFA goal date of S...

 PRESS RELEASE

Partex and Fortress Biotech Announce Strategic Collaboration to Accele...

Partex and Fortress Biotech Announce Strategic Collaboration to Accelerate Asset Identification and Evaluation Using Proprietary AI Platform FRANKFURT, Germany and MIAMI, March 17, 2025 (GLOBE NEWSWIRE) -- Partex NV and Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company, today announced a strategic collaboration aimed at identifying and evaluating biopharmaceutical compounds using artificial intelligence (AI) for potential acquisition or licensing by Fortress. Partex will deploy its proprietary AI-based drug discovery and development technology pl...

 PRESS RELEASE

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Tri...

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT Study is the first randomized, controlled trial examining a vaccine’s effectiveness in controlling CMV in recipients of HSCT from vaccinated donors Encouraging pilot study results demonstrated the benefit of vaccinating donors with Triplex to convey protective CMV-specific T cell immunity to allogeneic HSCT recipients at risk for CMV reactivation MIAMI, Jan. 27, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fort...

 PRESS RELEASE

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance...

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive royalties and up to $129 million in aggregate development and sales milestones Cyprium also retains ownership over any Priority Review Voucher that may be issued at NDA approval MIAMI, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) and its majority-owned subsidiary, Cyprium Therapeutics, In...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch